Drug Facts
Composition & Profile
Identifiers & Packaging
HOW SUPPLIED Klor-Con ® M10 Extended-release Tablets, contains 750 mg of potassium chloride (equivalent to 10 mEq of potassium) are white, oblong tablets and imprinted "KC M10". They are supplied as follows: Bottles of 90 tablets NDC 0245-5317-90 Bottles of 100 tablets NDC 0245-5317-11 Bottles of 1,000 tablets NDC 0245-5317-10 Unit-dose cartons of 100 tablets NDC 0245-5317-01 Klor-Con ® M15 Extended-release Tablets, contains 1,125 mg of potassium chloride (equivalent to 15 mEq of potassium) are white, oblong tablets and imprinted "M 15" and scored for flexibility of dosing. They are supplied as follows: Bottles of 100 tablets NDC 0245-5318-11 Unit-dose cartons of 100 tablets NDC 0245-5318-01 Klor-Con ® M20 Extended-release Tablets, contains 1,500 mg of potassium chloride (equivalent to 20 mEq of potassium) are white, oblong tablets and imprinted "KC M20" and scored for flexibility of dosing. They are supplied as follows: Bottles of 90 tablets NDC 0245-5319-90 Bottles of 100 tablets NDC 0245-5319-11 Bottles of 500 tablets NDC 0245-5319-15 Bottles of 1,000 tablets NDC 0245-5319-10 Unit-dose cartons of 100 tablets NDC 0245-5319-01 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Keep tightly closed.; PRINCIPAL DISPLAY PANEL - 10 mEq K Tablet Bottle Label NDC 0245-5317-11 Klor-Con ® M10 Potassium Chloride Extended-Release Tablets, USP MICRO-DISPERSIBLE TECHNOLOGY ® 10 mEq K 100 Tablets Rx only UPSHER-SMITH PRINCIPAL DISPLAY PANEL - 10 mEq K Tablet Bottle Label; PRINCIPAL DISPLAY PANEL - 15 mEq K Tablet Bottle Label NDC 0245-5318-11 Klor-Con ® M15 Potassium Chloride Extended-Release Tablets, USP MICRO-DISPERSIBLE TECHNOLOGY ® 15 mEq K 100 Tablets Rx only UPSHER-SMITH PRINCIPAL DISPLAY PANEL - 15 mEq K Tablet Bottle Label; PRINCIPAL DISPLAY PANEL - 20 mEq K Tablet Bottle Label NDC 0245-5319-11 Klor-Con ® M20 Potassium Chloride Extended-Release Tablets, USP MICRO-DISPERSIBLE TECHNOLOGY ® 20 mEq K 100 Tablets Rx only UPSHER-SMITH PRINCIPAL DISPLAY PANEL - 20 mEq K Tablet Bottle Label
- HOW SUPPLIED Klor-Con ® M10 Extended-release Tablets, contains 750 mg of potassium chloride (equivalent to 10 mEq of potassium) are white, oblong tablets and imprinted "KC M10". They are supplied as follows: Bottles of 90 tablets NDC 0245-5317-90 Bottles of 100 tablets NDC 0245-5317-11 Bottles of 1,000 tablets NDC 0245-5317-10 Unit-dose cartons of 100 tablets NDC 0245-5317-01 Klor-Con ® M15 Extended-release Tablets, contains 1,125 mg of potassium chloride (equivalent to 15 mEq of potassium) are white, oblong tablets and imprinted "M 15" and scored for flexibility of dosing. They are supplied as follows: Bottles of 100 tablets NDC 0245-5318-11 Unit-dose cartons of 100 tablets NDC 0245-5318-01 Klor-Con ® M20 Extended-release Tablets, contains 1,500 mg of potassium chloride (equivalent to 20 mEq of potassium) are white, oblong tablets and imprinted "KC M20" and scored for flexibility of dosing. They are supplied as follows: Bottles of 90 tablets NDC 0245-5319-90 Bottles of 100 tablets NDC 0245-5319-11 Bottles of 500 tablets NDC 0245-5319-15 Bottles of 1,000 tablets NDC 0245-5319-10 Unit-dose cartons of 100 tablets NDC 0245-5319-01 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Keep tightly closed.
- PRINCIPAL DISPLAY PANEL - 10 mEq K Tablet Bottle Label NDC 0245-5317-11 Klor-Con ® M10 Potassium Chloride Extended-Release Tablets, USP MICRO-DISPERSIBLE TECHNOLOGY ® 10 mEq K 100 Tablets Rx only UPSHER-SMITH PRINCIPAL DISPLAY PANEL - 10 mEq K Tablet Bottle Label
- PRINCIPAL DISPLAY PANEL - 15 mEq K Tablet Bottle Label NDC 0245-5318-11 Klor-Con ® M15 Potassium Chloride Extended-Release Tablets, USP MICRO-DISPERSIBLE TECHNOLOGY ® 15 mEq K 100 Tablets Rx only UPSHER-SMITH PRINCIPAL DISPLAY PANEL - 15 mEq K Tablet Bottle Label
- PRINCIPAL DISPLAY PANEL - 20 mEq K Tablet Bottle Label NDC 0245-5319-11 Klor-Con ® M20 Potassium Chloride Extended-Release Tablets, USP MICRO-DISPERSIBLE TECHNOLOGY ® 20 mEq K 100 Tablets Rx only UPSHER-SMITH PRINCIPAL DISPLAY PANEL - 20 mEq K Tablet Bottle Label
Overview
Klor-Con ® M10 (potassium chloride extended-release tablets, USP) is an immediately dispersing extended-release oral dosage form of potassium chloride containing 750 mg of microencapsulated potassium chloride, USP equivalent to 10 mEq of potassium in a tablet. Klor-Con ® M15 (potassium chloride extended-release tablets, USP) is an immediately dispersing extended-release oral dosage form of potassium chloride containing 1,125 mg of microencapsulated potassium chloride, USP equivalent to 15 mEq of potassium in a tablet. Klor-Con ® M20 (potassium chloride extended-release tablets, USP) is an immediately dispersing extended-release oral dosage form of potassium chloride containing 1,500 mg of microencapsulated potassium chloride, USP equivalent to 20 mEq of potassium in a tablet. These formulations are intended to slow the release of potassium so that the likelihood of a high localized concentration of potassium chloride within the gastrointestinal tract is reduced. Klor-Con ® M is an electrolyte replenisher. The chemical name of the active ingredient is potassium chloride, and the structural formula is KCl. Potassium chloride, USP occurs as a white, granular powder or as colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol. Klor-Con ® M is a tablet formulation (not enteric-coated or wax matrix) containing individually microencapsulated potassium chloride crystals which disperse upon tablet disintegration. In simulated gastric fluid at 37°C and in the absence of outside agitation, Klor-Con ® M begins disintegrating into microencapsulated crystals within seconds and completely disintegrates within 1 minute. The microencapsulated crystals are formulated to provide an extended-release of potassium chloride, USP. Inactive Ingredients : croscarmellose sodium, ethylcellulose and microcrystalline cellulose.
Indications & Usage
BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated.
Dosage & Administration
The usual dietary intake of potassium by the average adult is 50 to 100 mEq per day. Potassium depletion sufficient to cause hypokalemia usually requires the loss of 200 or more mEq of potassium from the total body store. Dosage must be adjusted to the individual needs of each patient. The dose for the prevention of hypokalemia is typically in the range of 20 mEq per day. Doses of 40 to 100 mEq per day or more are used for the treatment of potassium depletion. Dosage should be divided if more than 20 mEq per day is given such that no more than 20 mEq is given in a single dose. Each Klor-Con ® M10 tablet provides 750 mg of potassium chloride equivalent to 10 mEq of potassium. Each Klor-Con ® M15 tablet provides 1125 mg of potassium chloride equivalent to 15 mEq of potassium. Each Klor-Con ® M20 tablet provides 1500 mg of potassium chloride equivalent to 20 mEq of potassium. Klor-Con M tablets should be taken with meals and with a glass of water or other liquid. This product should not be taken on an empty stomach because of its potential for gastric irritation [see WARNINGS ]. Patients having difficulty swallowing whole tablets may try one of the following alternate methods of administration: Break the tablet in half and take each half separately with a glass of water. Prepare an aqueous (water) suspension as follows: Place the whole tablet(s) in approximately ½ glass of water (4 fluid ounces). Allow approximately 2 minutes for the tablet(s) to disintegrate. Stir for about half a minute after the tablet(s) has disintegrated. Swirl the suspension and consume the entire contents of the glass immediately by drinking or by the use of a straw. Add another 1 fluid ounce of water, swirl, and consume immediately. Then, add an additional 1 fluid ounce of water, swirl, and consume immediately. Aqueous suspension of potassium chloride that is not taken immediately should be discarded. The use of other liquids for suspending potassium chloride is not recommended.
Warnings & Precautions
WARNINGS Hyperkalemia [see OVERDOSAGE ] In patients with impaired mechanisms for excreting potassium, the administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment. Interaction with Potassium-Sparing Diuretics Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene, or amiloride) since the simultaneous administration of these agents can produce severe hyperkalemia. Interaction with Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. Interaction with Nonsteroidal Anti-Inflammatory Drugs Nonsteroidal anti-inflammatory drugs (NSAIDs) may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients receiving concomitant NSAID therapy. Gastrointestinal Lesions Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract. Based on spontaneous adverse reaction reports, enteric-coated preparations of potassium chloride are associated with an increased frequency of small bowel lesions (40 to 50 per 100,000 patient years) compared to sustained-release wax matrix formulations (less than one per 100,000 patient years). Because of the lack of extensive marketing experience with microencapsulated products, a comparison between such products and wax matrix or enteric-coated products is not available. Klor-Con M is a tablet formulated to provide an controlled rate of release of microencapsulated potassium chloride and thus to minimize the possibility of a high local concentration of potassium near the gastrointestinal wall. Prospective trials have been conducted in normal human volunteers in which the upper gastrointestinal tract was evaluated by endoscopic inspection before and after 1 week of solid oral potassium chloride therapy. The ability of this model to predict events occurring in usual clinical practice is unknown. Trials which approximated usual clinical practice did not reveal any clear differences between the wax matrix and microencapsulated dosage forms. In contrast, there was a higher incidence of gastric and duodenal lesions in subjects receiving a high dose of a wax matrix controlled-release formulation under conditions which did not resemble usual or recommended clinical practice (i.e., 96 mEq per day in divided doses of potassium chloride administered to fasted patients, in the presence of an anticholinergic drug to delay gastric emptying). The upper gastrointestinal lesions observed by endoscopy were asymptomatic and were not accompanied by evidence of bleeding (Hemoccult testing). The relevance of these findings to the usual conditions (i.e., non-fasting, no anticholinergic agent, smaller doses) under which controlled-release potassium chloride products are used is uncertain; epidemiologic studies have not identified an elevated risk, compared to microencapsulated products, for upper gastrointestinal lesions in patients receiving wax matrix formulations. Klor-Con M tablets should be discontinued immediately, and the possibility of ulceration, obstruction, or perforation should be considered if severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs. Metabolic Acidosis Hypokalemia in patients with metabolic acidosis should be treated with an alkalinizing potassium salt such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.
Contraindications
Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis, such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene, or amiloride) [see OVERDOSAGE ]. Controlled-release formulations of potassium chloride have produced esophageal ulceration in certain cardiac patients with esophageal compression due to enlarged left atrium. Potassium supplementation, when indicated in such patients, should be given as a liquid preparation or as an aqueous (water) suspension of potassium chloride [see PRECAUTIONS: Information for Patients and DOSAGE AND ADMINISTRATION ]. All solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological (e.g., diabetic gastroparesis), or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in tablet passage through the gastrointestinal tract.
Adverse Reactions
One of the most severe adverse effects is hyperkalemia [see CONTRAINDICATIONS , WARNINGS and OVERDOSAGE ]. There have also been reports of upper and lower gastrointestinal conditions including obstruction, bleeding, ulceration, and perforation [see CONTRAINDICATIONS and WARNINGS ]. The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals or reducing the amount taken at one time.
Drug Interactions
Potassium-sparing diuretics, angiotensin-converting enzyme inhibitors [see WARNINGS ].
Storage & Handling
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Keep tightly closed.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.